The role of NGF in the pain development has also been demonstrated by studies evaluating the efficacy of using anti-NGF antibodies (tanezumab) for the treatment of knee and hip osteoarthritis, suggesting that NGF signalling inhibition, involving activation of TrkA and p75NTR receptors, may represent a viable pain management strategy in osteoarthritic patients [120]. Here, NGF is linked to phosphoglycerides measurement .